2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172895
    Quorum sensing-IN-10
    Quorum sensing-IN-10 (10p), an antibacterial synergist, shows significant inhibition of P. aeruginosa virulence, biofilm, and motility, with low toxicity. Quorum sensing-IN-10 (10p) can be used in the research for drug-resistant Pseudomonas aeruginosa infections.
    Quorum sensing-IN-10
  • HY-172903
    Nav1.8-IN-16
    Nav1.8-IN-16 (Compound (R)-40) is an orally active and selective hNaV 1.8 inhibitor (IC50: 5.9 nM). Nav1.8-IN-16 exerts analgesic effects by blocking NaV1.8 channels without significantly affecting other NaV subtypes or hERG channels. Nav1.8-IN-16 exhibits dose-dependent analgesic effects in postoperative pain and inflammatory pain models and can be used in pain-related research.
    Nav1.8-IN-16
  • HY-172909
    RIPK3-IN-5
    RIPK3-IN-5 (compound 32) is a potent RIPK3 inhibitor with an IC50 of 27 nM. RIPK3-IN-5 also inhibits necroptosis with an EC50 of 0.45 μM.
    RIPK3-IN-5
  • HY-172920
    Wnt/β-catenin-IN-6
    Wnt/β-catenin-IN-6 (compound B10) is a potent Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 inhibits A549 cells activity with an IC50 of 1.28 μM.
    Wnt/β-catenin-IN-6
  • HY-173003
    EP-3945 3057176-00-5
    EP-3945 is a potent agonist of Mas-related G protein-coupled receptor (MRGPR), more effective than the MRGPRD small molecule agonist β-Alanine (HY-N0230). MRGPR plays a crucial role in inflammatory pruritus and pain sensation. Additionally, MRGPR binds to Gq (MRGPRX2, MRGPRX4, MRGPRX1 couple with Gq; MRGPRX2, MRGPRD couple with Gi), with EP-3945 measured EC50 for Gq being 211.6 nM.
    EP-3945
  • HY-173041
    Arginase inhibitor 9
    Arginase inhibitor 9 (Compound 12a) is an arginase inhibitor with IC50 values of 9 μM and 55 μM for bovine and human arginase I, respectively. Arginase inhibitor 9 exhibits antioxidant activity and can scavenge free radicals. Additionally, Arginase inhibitor 9 can effectively regulate the levels of collagen and procollagen, exerting an anti-fibrotic effect.
    Arginase inhibitor 9
  • HY-173046
    NLRP3-IN-71 3026419-44-0
    NLRP3-IN-71 (Compound 19) is a BBB-permeable, orally active and selective NLRP3 inhibitor that can inhibit IL-1β secretion. NLRP3-IN-71 can be used for the research of neurodegenerative diseases.
    NLRP3-IN-71
  • HY-173052
    SLW131 681511-84-2
    SLW131 (Compound 10) is the antagonist for CCR7 with a good affinity of Ki of 9.85 nM. SLW131 inhibits CCL19-induced Go protein activation with an IC50 of 29.4 μM, inhibits β-arrestin2 recruitment with an IC50 of 6.0 μM. SLW131 inhibits CCL19-induced cell morphological changes in primary BMDCs, and CCR7-mediated migration in mouse CD4+ T cell.
    SLW131
  • HY-173055
    Ferroleuton
    Ferroleuton is a competitive, selective inhibitor for 5-lipoxygenase with an IC50 of 0.21 μM. Ferroleuton exhibits antioxidant activity in DPPH (scavenges 86% DPPH-H at 50 μM), ABTS (EC50=19.42 μM) and FRAP (EC50=3.32 μM) assays.
    Ferroleuton
  • HY-173056
    Ruthenoleuton
    Ruthenoleuton is a 5-lipoxygenase (5-LOX) inhibitor with an IC50 of 3.49 μM and a Ki of 0.80 μM. Ruthenoleuton has antioxidant activity and can be used in the research of inflammatory diseases.
    Ruthenoleuton
  • HY-173063
    TLR8 antagonist-1 1111460-83-3
    TLR8 antagonist-1 (Compound 10) is a selective TLR8 antagonist. TLR8 antagonist-1 can inhibit TLR8-mediated inflammation and signaling pathways, reduce the recruitment of MyD88, and inhibit the NF-κB and IRF pathways. TLR8 antagonist-1 has anti-inflammatory activity.
    TLR8 antagonist-1
  • HY-173070
    TLR7 agonist 29
    TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC.
    TLR7 agonist 29
  • HY-173076
    HDAC11-IN-1
    HDAC11-IN-1 (Compound 14-NC6OH) is a selective macrocyclic inhibitor of HDAC11 with a Ki of 40 nM. HDAC11-IN-1 exhibits good cell permeability and can inhibit the expression of YAP1 and SOX2.
    HDAC11-IN-1
  • HY-173114
    Anti-inflammatory agent 96
    Anti-inflammatory agent 96 (Compound 5), a tetrasubstituted α-aminophosphonate derivatives with a methylphosphoserine fragment, is an anti-inflammatory agent. Anti-inflammatory agent 96 can reduce TPA-induced ear edema and CFA-induced paw edema.
    Anti-inflammatory agent 96
  • HY-173115
    15-LOX-IN-2
    15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases.
    15-LOX-IN-2
  • HY-173129
    Anti-inflammatory agent 97
    Anti-inflammatory agent 97 (Compound 1l), an anti-inflammation agent, can also inhibit oxidative stress. Anti-inflammatory agent 97 can inhibit the colonic shortening and suppress inflammatory symptoms of the colonic tissue in the DSS (HY-116282C)-induced ulcerative colitis mice model. Anti-inflammatory agent 97 can regulate the inflammation-related TLR4/NF-κB signaling pathway and the oxidative stress-related Nrf2/HO-1 signaling pathway.
    Anti-inflammatory agent 97
  • HY-173130
    α-Glucosidase-IN-86
    α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes.
    α-Glucosidase-IN-86
  • HY-173144
    AChE-IN-85
    AChE-IN-85 (Compound 7k) is an AChE inhibitor with an IC50 of 0.083 μM. AChE-IN-85 can inhibit the release of NO, the production of TNF-α and IL-1β, the levels of LDH and ROS, as well as the aggregation of Aβ42. AChE-IN-85 has anti-inflammatory and neuroprotective effects and can be used in the research of diseases such as Alzheimer's disease.
    AChE-IN-85
  • HY-173152
    AChE/BChE-IN-26
    AChE/BChE-IN-26 (Compound 20aa) is a cholinesterase inhibitor with IC50 values of 0.75 μM and 4.11 μM against eeAChE and eqBChE, respectively. AChE/BChE-IN-26 has antioxidant activity and can be used in the research of diseases such as Alzheimer's disease.
    AChE/BChE-IN-26
  • HY-173153
    BRAFV600E/JNK-IN-1
    BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3 and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM and 0.009 μM, respectively. BRAFV600E/JNK-IN-1 can inhibit the phosphorylation of MEK1/2 and ERK1/2. In addition, BRAFV600E/JNK-IN-1 can inhibit tumor cell proliferation, NO release and PGE2 production, and has anti-tumor and anti-inflammatory activities.
    BRAFV600E/JNK-IN-1
Cat. No. Product Name / Synonyms Application Reactivity